Free Trial
NYSE:AGE

AgeX Therapeutics (AGE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.22
$16.51
52-Week Range
N/A
Volume
3,700 shs
Average Volume
3,849 shs
Market Capitalization
$11.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AGE stock logo

About AgeX Therapeutics Stock (NYSE:AGE)

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

AGE Stock News Headlines

SER Serina Therapeutics, Inc.
AgeX Therapeutics Inc AGE
25 States with the Highest Life Expectancy in the US
See More Headlines
Receive AGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AgeX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
5
Year Founded
N/A

Profitability

Net Income
$-14,800,000.00
Net Margins
-10,424.65%
Pretax Margin
-10,430.28%

Debt

Sales & Book Value

Annual Sales
$140,000.00
Book Value
($16.07) per share

Miscellaneous

Free Float
1,008,000
Market Cap
$11.99 million
Optionable
Not Optionable
Beta
1.18
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Joanne M. Hackett Ph.D. (Age 46)
    Interim CEO & Chairman of the Board
    Comp: $55.74k
  • Ms. Eun-Jae Park CPA (Age 52)
    Chief Financial Officer
    Comp: $295.29k
  • Dr. Ivan Labat
    Chief Information Officer
  • Ms. Judith Segall (Age 71)
    Secretary

AGE Stock Analysis - Frequently Asked Questions

When did AgeX Therapeutics' stock split?

Shares of AgeX Therapeutics split on Monday, March 18th 2024. The 8-5 split was announced on Monday, March 18th 2024. The newly created shares were distributed to shareholders after the market closes on Monday, March 18th 2024. An investor that had 100 shares of stock prior to the split would have 160 shares after the split.

What other stocks do shareholders of AgeX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AgeX Therapeutics investors own include Biocept (BIOC), Allena Pharmaceuticals (ALNA), Co-Diagnostics (CODX), Moleculin Biotech (MBRX), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), AIM ImmunoTech (AIM), AzurRx BioPharma (AZRX) and Digital Ally (DGLY).

This page (NYSE:AGE) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners